This article has Open Peer Review reports available.
Response to imatinib rechallenge in a patient with a recurrent gastrointestinal stromal tumor after adjuvant therapy: a case report
© Kang; licensee BioMed Central Ltd. 2011
Received: 28 June 2011
Accepted: 5 October 2011
Published: 5 October 2011
Adjuvant imatinib improves recurrence-free survival of patients following resection of primary KIT-positive gastrointestinal stromal tumors. However, it is unknown whether patients who previously received adjuvant imatinib therapy will respond to imatinib rechallenge as treatment for recurrent disease. Here we present the first report documenting the benefits of imatinib rechallenge in a patient previously exposed to imatinib during adjuvant treatment.
A 51-year-old Asian woman with a wedge-resected primary gastric gastrointestinal stromal tumor at high risk of relapse underwent two years of adjuvant treatment with imatinib. Only 10 months after the completion of adjuvant imatinib treatment, a computed tomography scan revealed gastrointestinal stromal tumor recurrence in this patient, with multiple peritoneal nodules in the upper abdomen being detected. Our patient was rechallenged with imatinib 400 mg/day and had a partial response after one month of treatment. Imatinib rechallenge was well tolerated by our patient; the only adverse events she experienced were grade 1 edema, anemia and fatigue. Our patient maintained a partial response two years and six months after the imatinib rechallenge. However, computed tomography scans three months later showed that our patient had disease progression.
This case report demonstrates that a patient with a gastrointestinal stromal tumor who had previously received adjuvant imatinib therapy responded to imatinib rechallenge as treatment for her recurrent disease. These results indicate that imatinib sensitivity can be maintained in a patient with previous exposure to adjuvant imatinib therapy.
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. These tumors are characterized by activating mutations of either receptor tyrosine kinase KIT or, less commonly, platelet-derived growth factor receptor α (PDGFRα) . Imatinib mesylate, an oral selective inhibitor of KIT and PDGFRα, is approved for the treatment of adult patients with unresectable and/or metastatic KIT-positive (KIT+) GIST. It is also indicated for the adjuvant treatment of adult patients following resection of GIST . Current guidelines [3, 4] recommend adjuvant treatment with imatinib for at least one year and the use of risk assessment systems based on the main variables of mitotic rate, tumor size, tumor site and tumor rupture to guide patient selection for adjuvant imatinib therapy. This recommendation is based on results from the pivotal American College of Surgeons Oncology Group (ACOSOG) Z9001 trial. This trial demonstrated a significant one-year recurrence-free survival (RFS) benefit for adjuvant imatinib versus placebo after the treatments were given for one year in patients at various levels of risk for recurrence . However, optimal duration of adjuvant imatinib has not yet been determined, and a longer course of therapy may be needed for patients at higher risk of recurrence.
A recent Korean, single-arm, Phase II study evaluated the efficacy of two years of adjuvant imatinib treatment in GIST patients with KIT exon 11 mutations who are at high risk of relapse following surgical resection of the primary GIST . The study showed a two-year RFS rate of 93.3%, which compared favorably with an RFS of 73% at two years after one year of adjuvant imatinib therapy in a similar patient population, reported in another single-arm, Phase II study (ACOSOG Z9000) . These results suggest that a longer duration of adjuvant imatinib treatment may improve the RFS of patients with KIT+ GIST after surgery. However, it is unclear whether this improvement in RFS will ultimately extend overall survival (OS) in these patients. One of the critical factors that will affect OS improvement is the effect of adjuvant therapy on the efficacy of imatinib rechallenge for treating recurrent disease. Although the results of another trial (BFR14) showed that most patients with progressive metastatic GIST were able to respond to imatinib rechallenge after treatment interruption , it remains to be determined whether imatinib sensitivity could also be maintained after completion of adjuvant treatment. Here, we report on a patient who responded to rechallenge with imatinib after experiencing recurrence subsequent to completion of two years of adjuvant imatinib therapy.
A 51-year-old Asian woman diagnosed with a primary gastric GIST underwent wedge resection, achieving complete removal of the entire tumor with microscopic examination of the margins showing no tumor cells (R0 margins). She was considered at high risk for recurrence based on the tumor size (8 cm × 7 cm × 3 cm) and high mitotic rate (>50 mitoses per 50 high powered fields (HPF)) of the excised GIST [9, 10]. In addition, mutation analysis showed that the tumor had KIT exon 11 deletions, a genotype shown to be associated with adverse outcomes after surgery . As such, our patient was enrolled in the aforementioned Korean Phase II trial of adjuvant imatinib for patients with localized KIT exon 11-mutant GIST at high risk of relapse . Our patient was started on imatinib adjuvant treatment 400 mg/day but developed a skin rash after three months; the rash was successfully managed with a temporary (three-week) dose interruption. Our patient was subsequently restarted on imatinib 300 mg/day and resumed taking standard-dose imatinib 400 mg/day after three months. She was maintained, generally tolerated this dose and completed the two-year adjuvant therapy regimen.
The results of this case report demonstrate that a GIST patient who has undergone adjuvant imatinib therapy responded when rechallenged with imatinib as a treatment for her recurrent disease. These results suggest that sensitivity to imatinib was not compromised by prior exposure to adjuvant imatinib.
The Korean adjuvant Phase II study referred to in this case report enrolled patients with resected primary GIST possessing KIT exon 11 mutations at high risk of recurrence (mitotic rate ≥5 mitoses/50 HPF and tumor size ≥5 cm, or mitotic rate ≥10 mitoses/50 HPF, or tumor size ≥10 cm) [9, 10]. Our previous retrospective study showed that the presence of KIT mutations, along with a high mitotic rate and larger tumor size, was an independent risk factor for poor prognosis in patients with localized GIST . Because GIST harboring KIT exon 11 mutations appeared to be more sensitive to imatinib treatment than GIST of other genotypes in the metastatic setting  and, shown more recently, in the adjuvant setting , patients with KIT exon 11 mutations at high risk of recurrence would be most likely to benefit from adjuvant treatment with imatinib. The fact that some patients, including our patient described in this case report, developed disease recurrence after stopping adjuvant therapy suggests that two years of adjuvant imatinib treatment may not be sufficient for eradicating residual GIST tumor cells and preventing relapse in these high-risk patients. Our patient's residual tumor cells remained sensitive to imatinib therapy, as evidenced by her good response to subsequent imatinib rechallenge. However, it appears that the sensitive residual tumor cells need to be continuously suppressed with adjuvant imatinib therapy to prevent or further delay disease recurrence. The question of how long patients should be treated with adjuvant imatinib remains. The Phase III study conducted by the Scandinavian Sarcoma Group (SSG) and the Sarcoma Group of the Arbeitsgemeinschaft Internistische Onkologie (AIO; SSGXVIII/AIO study) recently demonstrated that three years of adjuvant imatinib treatment, compared with one year of imatinib treatment, significantly improves RFS and OS in GIST patients who have a high estimated risk of recurrence after surgery . This suggests that patients at high risk of recurrence, such as our patient described in this case report, should receive adjuvant imatinib treatment for a minimum duration of three years. This is reflected in the updated National Comprehensive Cancer Network guidelines that, based on the results of the SSGXVIII/AIO trial, recommend considering adjuvant imatinib for at least 36 months for patients with high-risk GIST .
Our patient in this case report remained progression-free for two years and nine months, which is shorter than the median progression-free survival (PFS) of approximately four years achieved in a Korean Phase II study of patients with advanced GIST , but longer than the median PFS of 18 to 20 months reported in other studies of imatinib therapy for metastatic or recurrent GIST . Although it is not feasible to compare the results of clinical studies conducted in different patient populations at different times, the 33 months of PFS we observed in this case report suggest that our patient maintained sensitivity to imatinib even though she was previously exposed to imatinib for two years in the adjuvant setting.
Rechallenge with imatinib may provide substantial clinical benefit to patients with recurrent GIST after cessation of adjuvant imatinib therapy.
Written informed consent was obtained from our patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. I thank Jinling Wu, MD, PhD, for her medical editorial assistance with this manuscript.
- Corless CL, Heinrich MC: Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. 2008, 3: 557-586. 10.1146/annurev.pathmechdis.3.121806.151538.View ArticlePubMedGoogle Scholar
- Novartis Pharmaceuticals: Gleevec/Glivec prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf
- Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD: NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010, 8 (Suppl 2): S1-S41.PubMedPubMed CentralGoogle Scholar
- Kang YK, Kim KM, Sohn T, Choi D, Kang HJ, Ryu MH, Kim WH, Yang HK, Korean GIST Study Group: Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. J Korean Med Sci. 2010, 25: 1543-1552. 10.3346/jkms.2010.25.11.1543.View ArticlePubMedPubMed CentralGoogle Scholar
- DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009, 373: 1097-1104. 10.1016/S0140-6736(09)60500-6.View ArticlePubMedPubMed CentralGoogle Scholar
- Kang B, Lee J, Ryu M, Im S, Park S, Kang W, Kim T, Oh D, Jung K, Kang Y: A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors. J Clin Oncol (Meeting Abstracts). 2009, 27: e21515-Google Scholar
- DeMatteo RP, Owzar K, Antonescu CR, Maki R, Demetri GD, McCarter M, von Mehren M, Pisters P, Brennan MF, Ballman KV: Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000 [abstract]. http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10450
- Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D: Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007, 25: 1107-1113. 10.1200/JCO.2006.09.0183.View ArticlePubMedGoogle Scholar
- Joensuu H: Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008, 39: 1411-1419. 10.1016/j.humpath.2008.06.025.View ArticlePubMedGoogle Scholar
- Kim TW, Lee H, Kang YK, Choe MS, Ryu MH, Chang HM, Kim JS, Yook JH, Kim BS, Lee JS: Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res. 2004, 10: 3076-3081. 10.1158/1078-0432.CCR-03-0581.View ArticlePubMedGoogle Scholar
- Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003, 21: 4342-4349. 10.1200/JCO.2003.04.190.View ArticlePubMedGoogle Scholar
- Corless CL, Ballman KV, Antonescu C, Blanke CD, Blackstein ME, Demetri GD, von Mehren M, Maki RG, Pisters PW, DeMatteo RP, American College of Surgeons Oncology Group: Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol (Meeting Abstracts). 2010, 28: 10006-Google Scholar
- Joensuu H, Eriksson M, Hatrmann J, Sundby Hall K, Schutte J, Reichardt A, Schlemmer M, Wardelmann E, Ramadori G, Al-Batran S, Nilsson E, Monge O, Kallio R, Sarlomo-Rikala M, Bono P, Leinonen M, Hohenberger P, Alvegard T, Reichardt P: Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial [abstract] (SSGXVIII/AIO). J Clin Oncol. 2011, 29 (suppl): LBA1-Google Scholar
- National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version2.2011 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
- Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK: A prospective, multicenter, phase 2 study of imatinib mesylate in Korean patients with metastatic or unresectable gastrointestinal stromal tumor. Oncology. 2009, 76: 326-332. 10.1159/000209384.View ArticlePubMedGoogle Scholar
- Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008, 26: 626-632. 10.1200/JCO.2007.13.4452. http://jco.ascopubs.org/content/26/4/626.full?sid=f8b759be-e0a9-4e0d-ba3a-1807629ebd74 View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.